ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sacubitril

Also written as “sacubitril/valsartan”, “Experimental: Sacubitril/Allisartan and Amlodipine Group” and “AHU377”.

Its studies are mostly in Heart Failure · Essential Hypertension · Chagas Disease · Myocardial Infarction · Isolated Systolic Hypertension, led by 4 companies.

Drug pageSacubitril: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 10, 201913 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis80 open or runningphase 4since Jul 10, 2019Oct 5, 2007none ahead
Shenzhen Salubris Pharmaceuticalsits history only20 open or runningphase 3since Jul 9, 2026Jul 9, 2026none ahead
Viatrisits history only22 open or runningphase 1since Jan 25, 2024Jan 25, 2024none ahead
Dr. Reddy's Laboratoriesits history only11 open or runningphase 1since Dec 12, 2023Dec 12, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2007First study: phase 2 study in HypertensionFirst studyNCT00549770 · 1,334 enrolled · United States, Argentina, Canada and more
  2. Jan 20, 2011Phase 2 study in Isolated Systolic HypertensionNCT01281306 · 910 enrolled · United States, Argentina, Canada and more
  3. Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
  4. Dec 20, 2018Phase 3 study in Heart FailureNCT03785405 · 216 enrolled · United States, Argentina, Austria and more
  5. Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)NCT03988634 · 467 enrolled · United States, Canada
  6. Jul 10, 2019Phase 4 study in Chagas DiseaseNCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
  7. Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNCT04637555
  8. Nov 13, 2023Phase 3 study in Heart FailureNCT06149104 · 8 enrolled · Japan

TargetBeta

DDR1 →MME →read by rule
“A neprilysn (NEP) inhibitor prodrug with natriuretic activity”NCIt, by rule
“Neprilysin inhibitor”ChEMBL 37, by rule

Studies

All 8 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06149104Heart Failure · Japan3CompletedAug 14, 20248
NCT04637555Post Myocardial Infarction3WithdrawnJun 1, 20230
NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more4CompletedMar 16, 2025922
NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada3CompletedDec 14, 2022467
NCT03785405Heart Failure · United States, Argentina, Austria and more3CompletedDec 29, 2023216
NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more3CompletedOct 28, 20192,572
NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more2CompletedDec 2011910
NCT00549770Hypertension · United States, Argentina, Canada and more2CompletedJul 20081,334

How it is read

Names in the registry

  • “sacubitril/valsartan”, 5 entries
  • “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries
  • “AHU377”, 2 entries
  • “Sacubitril/valsartan”, 1 entry
  • “Sacubitril and Valsartan Tablets 49mg/51mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.